" class="no-js "lang="en-US"> Regeneron - Medtech Alert
Friday, August 01, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Regeneron | Pharmtech Focus

Regeneron

About Regeneron

Regeneron

Get in the Ideas Business. At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work together to discover, invent, and develop biopharmaceutical medicines, we’re creating whole new ways of thinking about science, manufacturing and commercialization. And whole new ways of thinking about health. So connect with us. Tell us about you. Learn more about our life-changing medicines. And join us, as we build a future we believe in. Please visit www.regeneron.com/social-media-terms for more information on how to engage with Regeneron on social media.

Related Story

Drug Development

 Alnylam & Regeneron Report Positive Data on ALN-APP, an Investigational Therapeutic for Alzheimer’s Disease & Cerebral Amyloid Angiopathy | MTA

Alnylam & Regeneron Report Positive Data on ALN-APP, an Investigational Therapeutic for Alzheimer’s Disease & Cerebral Amyloid Angiopathy

April 27 2023

Alnylam Pharmaceuticals and Regeneron Pharmaceuticals announced today positive interim results from the ongoing single ascending […]

News

 Sonoma Biotherapeutics and Regeneron Announce Collaboration to Discover, Develop and Commercialize T Cell Therapies | MTA

Sonoma Biotherapeutics and Regeneron Announce Collaboration to Discover, Develop and Commercialize T Cell Therapies

March 28 2023

Sonoma Biotherapeutics and Regeneron Pharmaceuticals today announced a collaboration to apply their scientific and clinical expertise […]

News

 Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis | MTA

Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis

March 21 2023

Regeneron Pharmaceuticals and Sanofi today announced that the European Commission (EC) has approved Dupixent (dupilumab) […]

Diseases

 Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Eosinophilic Esophagitis | PTF

Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Eosinophilic Esophagitis

January 30 2023

Regeneron Pharmaceuticals and Sanofi today announced that the European Commission (EC) expanded the marketing authorization […]

Diseases

 Regeneron and CytomX Announce Strategic Research Collaboration for Cancer Treatment | PTF

Regeneron and CytomX Announce Strategic Research Collaboration for Cancer Treatment

November 23 2022

Regeneron Pharmaceuticals and CytomX Therapeutics has announced a collaboration and licensing agreement to create conditionally-activated […]

Companies

 BioNTech and Regeneron Expand Strategic Collaboration to Advance Clinical Development of FixVac and Libtayo® (cemiplimab) Combination in NSCLC | Pharmtech Focus

BioNTech and Regeneron Expand Strategic Collaboration to Advance Clinical Development of FixVac and Libtayo® (cemiplimab) Combination in NSCLC

March 9 2022

BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced the expansion of its strategic collaboration […]

Clinical Trials

 New Phase 3 Analyses Show That a Single Dose of REGEN-COV® (casirivimab and imdevimab) Provides Long-term Protection Against COVID-19 | Pharmtech Focus

New Phase 3 Analyses Show That a Single Dose of REGEN-COV® (casirivimab and imdevimab) Provides Long-term Protection Against COVID-19

November 8 2021

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced additional positive results from a Phase 3 trial jointly run with the […]

COVID-19

 First Monoclonal Antibody Treatment for COVID-19 Approved for Use in the UK | Pharmtech Focus

First Monoclonal Antibody Treatment for COVID-19 Approved for Use in the UK

August 20 2021

Following on from a thorough review of the evidence carried out by the MHRA, and […]

Diseases

 Libtayo ® (Cemiplimab) Receives Positive CHMP Opinion for the Treatment in Europe of Two Advanced Cancers | Pharmtech Focus

Libtayo ® (Cemiplimab) Receives Positive CHMP Opinion for the Treatment in Europe of Two Advanced Cancers

May 25 2021

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted […]